SOPHiA GENETICS Launches MSK-IMPACT® Flex powered with SOPHiA DDM™ for Agile and Modular Comprehensive Genomic Profiling

New solution brings flexibility, efficiency, and scalability to precision oncology testing

BOSTON, MA and ROLLE, Switzerland, September 5, 2025 - SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced the launch of MSK-IMPACT® Flex powered with SOPHiA DDM^TM from the European Congress of Pathology. This latest innovation is designed to advance efficiencies and meaningful clinical comprehensive genomic profiling (CGP) insights. Built on the proven backbone of MSK-IMPACT® combined with the cloud-based SOPHiA DDM™ Platform, MSK-IMPACT® Flex empowers laboratories to achieve flexible, cost-efficient insights into key solid tumor biomarkers.

MSK-IMPACT® Flex powered with SOPHiA DDM^TM provides a holistic view of tumor biology by enabling analysis of DNA and RNA biomarkers across all major variant classes. The solution incorporates gene expression, key signatures such as TMB, MSI, and HRD, as well as high-resolution CNV detection, allowing labs to tailor biomarker testing to each case.

"Traditional approaches to CGP often require multiple assays, leading to fragmented workflows. MSK-IMPACT® Flex powered with SOPHiA DDM^TM changes that by combining expert-designed content with the adaptive analytics enabled by SOPHiA DDM^TM. The result is a single, streamlined solution that delivers flexibility without compromise, helping labs advance precision oncology at scale." said Philippe Menu, M.D., Ph.D, Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS.

Key advantages of MSK-IMPACT® Flex powered with SOPHiA DDM^TM include:

• Expert content design: Built on the backbone of MSK-IMPACT®, curated by Memorial Sloan Kettering Cancer Center experts, with validation in over 1000 publications.
• Comprehensive profiling: Detection of all major variant classes (SNVs, indels, CNVs, partner-agonstic fusions, exon-skipping events, gene expression) and complex signatures (TMB, MSI, HRD).
• In-depth CNV profiling: High-resolution CNV detection including whole gene amplifications/deletions and exon-level CNVs.
• Sample-level modularity: Ensures clinical relevance and cost efficiency by tailoring biomarker coverage based on each patient case.
• Operational efficiency: Tumor-only approach with robust analytical performance.
• End-to-end solution: From sample to report, with fully integrated analytics, interpretation, reporting, and data storage in SOPHiA DDM^TM.
• Maximized lab efficiency: Enabled by automated, streamlined workflows for DNA, RNA, and HRD testing.

This launch furthers SOPHiA GENETICS' mission to democratize data-driven medicine, bringing the latest advancements in genomic testing to healthcare institutions and patients around the world.

Learn more by connecting with SOPHiA GENETICS at the European Congress of Pathology in Vienna, Austria, September 6-9, 2025, or by visiting SOPHiAGENETICS.COM and LinkedIn.

Learn more about MSK-IMPACT® Flex powered with SOPHiA DDM™ .

Book a call to explore MSK-IMPACT® Flex powered with SOPHiA DDM™ .

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:
[email protected]